Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target upped by Oppenheimer from $40.00 to $46.00 in a report released on Monday morning, Marketbeat reports. The firm currently has an outperform rating on the stock. Other research analysts also recently issued reports about the company. HC Wainwright reissued a buy rating and issued a […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report)’s share price gapped up before the market opened on Tuesday after Evercore ISI raised their price target on the stock from $41.00 to $48.00. The stock had previously closed at $26.08, but opened at $27.00. Evercore ISI currently has an outperform rating on the stock. Crinetics Pharmaceuticals […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) saw some unusual options trading activity on Tuesday. Stock traders bought 2,787 put options on the company. This represents an increase of 269% compared to the typical volume of 756 put options. Insider Activity In other news, CFO Marc Wilson sold 30,922 shares of the firm’s stock […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target lifted by analysts at Robert W. Baird from $43.00 to $45.00 in a note issued to investors on Monday, FlyOnTheWall reports. Robert W. Baird’s target price points to a potential upside of 181.78% from the stock’s current price. A number of other analysts also […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target upped by Evercore ISI from $41.00 to $48.00 in a research report issued to clients and investors on Monday, FlyOnTheWall reports. Evercore ISI’s target price would indicate a potential upside of 200.56% from the company’s previous close. A number of other research firms also […]